HRO761 + pembrolizumab + irinotecan
Phase 1Active 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
Conditions
MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
Trial Timeline
Jun 27, 2023 → Aug 31, 2027
NCT ID
NCT05838768About HRO761 + pembrolizumab + irinotecan
HRO761 + pembrolizumab + irinotecan is a phase 1 stage product being developed by Novartis for MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers. The current trial status is active. This product is registered under clinical trial identifier NCT05838768. Target conditions include MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05838768 | Phase 1 | Active |